• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » International Biomedical Research Alliance appoints Jeffrey I. Auerbach to board

International Biomedical Research Alliance appoints Jeffrey I. Auerbach to board

October 11, 2016
CenterWatch Staff

The International Biomedical Research Alliance, a nonprofit organization which provides programming and funding support for the NIH Oxford-Cambridge Scholars Program, has announced that Jeffrey I. Auerbach, Ph.D., is joining the Alliance’s board of directors. Dr. Auerbach is the founder and managing member of AuerbachSchrot, an intellectual property (IP) law firm based in Rockville, Md.

“The International Biomedical Research Alliance is always looking for new ways to support the NIH Oxford-Cambridge scholars and broaden their postgraduate medical research training. By partnering with Dr. Auerbach, who has 30 years’ experience in patent licensing, and has provided  counsel for some of the most complex biotechnology cases, we will help increase their knowledge of  this important arena,” said Stephen M. McLean, chairman of the Alliance Board of Directors. “We are delighted that Dr. Auerbach has agreed to join our Board.”

“This is a wonderful opportunity to help mentor the next generation of medical researchers who are going to shape the future of healthcare,” said Dr. Auerbach. “As a medical researcher and a patent lawyer, I understand many of the questions and challenges that these scholars face and have the experience to be able to provide practical, tangible guidance.”

Dr. Auerbach prepares and litigates bioinformatics, diagnostics, genetics, microbiology, molecular biology and therapeutic patent applications. He is also an expert in protecting global patent rights. Furthermore, he has patents of his own for vaccine production and isothermal “rolling circle” nucleic acid amplification.

He is also an entrepreneur. Dr. Auerbach founded Replicon, a biotechnology company that used rolling circle amplification in diagnostics, genomics and therapeutics, in 1994 and served as its president for almost eight years until it was acquired by Biokit. He then founded DC Associates, a company that licensed nucleic acid amplification technologies, and was its president for more than a decade.

Dr. Auerbach has an MPhil and a PhD in molecular biophysics and biochemistry from Yale University. He also has a JD from the National Law Center of George Washington University.

Upcoming Events

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

  • VaccinewithNeedle-360x240.png

    2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

  • Dominate-360x240.png

    COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing